Pfizer Settles BYU's Long-Running Celebrex Suit

Law360, New York (May 1, 2012, 5:11 PM EDT) -- Pfizer Inc. said Tuesday that it has settled Brigham Young University's long-running contract and trade secrets lawsuit that claimed one of the school's professors discovered the enzyme behind the development of the drugmaker's anti-inflammatory drugs Bextra and Celebrex.

Both parties declined to release details of the settlement, which had not yet been filed with the District of Utah federal court at press time.

The settlement will resolve close to six years of litigation in which BYU accused Pfizer of breaching two parts of a research agreement...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.